Payment overview · 2025
General Payments
$601.65
15 reported records · 6 companies
Healthcare provider profile · identity verified
Christopher R Wizner, MD
Allopathic & Osteopathic Physicians|Internal Medicine · POWDER SPRINGS, GA · NPI 1902896293
Verified facts
What the public records show
CMS Open Payments records show Christopher R Wizner, MD received $601.65 in general payments during 2025 across 15 reported records.
Novo Nordisk Inc accounted for 36.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $218.98 | 36.4% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $153.03 | 25.4% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $137.25 | 22.8% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $61.32 | 10.2% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.63 | 2.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.44 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $601.65 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $137.98 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $123.67 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $120.65 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $61.32 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $32.38 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.63 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.44 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 92 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
61 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
52 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
92 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 473 | 139 |
| Atorvastatin Calcium | Atorvastatin Calcium | 417 | 134 |
| Losartan Potassium | Losartan Potassium | 330 | 92 |
| Levothyroxine Sodium | Levothyroxine Sodium | 305 | 81 |
| Gabapentin | Gabapentin | 304 | 83 |
| Omeprazole | Omeprazole | 292 | 77 |
| Lisinopril | Lisinopril | 286 | 88 |
| Metformin Hcl | Metformin Hcl | 286 | 87 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 282 | 84 |
| Alprazolam | Alprazolam | 274 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 230 | 67 |
| Tramadol Hcl | Tramadol Hcl | 224 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 216 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 207 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 194 | 64 |
| Clonazepam | Clonazepam | 177 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 176 | 46 |
| Zolpidem Tartrate | Zolpidem Tartrate | 166 | 35 |
| Glimepiride | Glimepiride | 161 | 48 |
| Meloxicam | Meloxicam | 138 | 36 |
| Allopurinol | Allopurinol | 131 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 131 | 30 |
| Metformin Hcl Er | Metformin Hcl | 127 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 116 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 116 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 112 | 33 |
| Celecoxib | Celecoxib | 108 | 30 |
| Eliquis | Apixaban | 108 | 31 |
| Furosemide | Furosemide | 108 | 39 |
| Trazodone Hcl | Trazodone Hcl | 104 | 25 |
| Alendronate Sodium | Alendronate Sodium | 102 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 101 | 23 |
| Carvedilol | Carvedilol | 99 | 30 |
| Ozempic | Semaglutide | 92 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 89 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 87 | 23 |
| Jardiance | Empagliflozin | 84 | 20 |
| Potassium Chloride | Potassium Chloride | 80 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 79 | 23 |
| Simvastatin | Simvastatin | 78 | 29 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 78 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 33 |
| Ezetimibe | Ezetimibe | 75 | 24 |
| Azithromycin | Azithromycin | 73 | 67 |
| Sertraline Hcl | Sertraline Hcl | 68 | 24 |
| Farxiga | Dapagliflozin Propanediol | 61 | 20 |
| Montelukast Sodium | Montelukast Sodium | 57 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 56 | 14 |
| Januvia | Sitagliptin Phosphate | 55 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | 14 |
| Bupropion Xl | Bupropion Hcl | 51 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 49 | 16 |
| Sucralfate | Sucralfate | 48 | 11 |
| Valacyclovir | Valacyclovir Hcl | 48 | 19 |
| Temazepam | Temazepam | 47 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 45 | 13 |
| Lorazepam | Lorazepam | 44 | suppressed |
| Diazepam | Diazepam | 43 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 43 | suppressed |
| Pregabalin | Pregabalin | 43 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | 12 |
| Risperidone | Risperidone | 41 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 40 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 39 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 39 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 17 |
| Memantine Hcl | Memantine Hcl | 36 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 36 | 12 |
| Amoxicillin | Amoxicillin | 34 | 31 |
| Famotidine | Famotidine | 33 | suppressed |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 32 | 25 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Glipizide | Glipizide | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 27 | suppressed |
| Brilinta | Ticagrelor | 27 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Cilostazol | Cilostazol | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 20 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 21 | 17 |
| Lovastatin | Lovastatin | 21 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Prednisone | Prednisone | 18 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 16 |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Humalog | Insulin Lispro | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Sprintec | Norgestimate-Ethinyl Estradiol | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Dotti | Estradiol | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $601.65 · 15 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, Ozempic, Rybelsus, SHINGRIX, VOQUEZNA, VRAYLAR, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error